Neoadjuvant adebrelimab combined with triplet chemotherapy for locally advanced resectable adenocarcinoma of esophagogastric junction: a prospective, single-arm, phase II feasibility and safety study

医学 肿瘤科 腺癌 食管胃交界处 内科学 化疗 临床研究阶段 放射科 新辅助治疗 胃腺癌 完全响应 食管腺癌 相(物质)
作者
Jinqiang Liu,Rui Zhang,Wei Zhou,Zhenshun Li,Guangwen Zhang,Li Yang,Aqiang Fan,Shushang Liu,Yan Miao,Hao Sun,Hong Liu,Mian Wang
出处
期刊:Journal of gastrointestinal oncology [AME Publishing Company]
卷期号:17 (2): 46-46 被引量:3
标识
DOI:10.21037/jgo-2026-0236
摘要

Background: Immune checkpoint inhibitors (ICIs) in combination with chemotherapy have become the standard treatment for advanced adenocarcinoma of the esophagogastric junction (AEG). While perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) remains the global standard for locally advanced resectable AEG, its substantial hematologic toxicity and perioperative tolerability concerns may limit broader adoption in some Asian patients in real-world clinical practice. This study aimed to assess the perioperative feasibility and safety of neoadjuvant adebrelimab combined with chemotherapy (nab-paclitaxel, lobaplatin, and S-1) in patients with resectable, locally advanced AEG. Methods: Between November 2023 and April 2025, 24 patients with clinically staged cT3-4aNanyM0 or cT1-2N+M0 resectable AEG were prospectively enrolled at a single center. Patients received two 3-week cycles of neoadjuvant adebrelimab plus nab-paclitaxel, lobaplatin, and S-1, followed by surgery scheduled 4-6 weeks after treatment completion. Survival follow-up was censored on 19 October 2025. The primary endpoint was pathological complete response (pCR) rate. Results: Among the 24 enrolled patients, the median age was 62 years, 83.3% were male, 37.5% had Siewert type III tumors and programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥1. Twenty patients (83.3%) subsequently underwent surgery, all achieving R0 resection. In the intention-to-treat (ITT) population, the pCR and major pathological response (MPR) rates were 16.7% [95% confidence interval (CI): 4.7-37.4%] and 29.2% (95% CI: 12.6-51.1%), respectively. Corresponding rates in the surgery population were 20.0% (95% CI: 5.7-43.7%) and 35.0% (95% CI: 15.4-59.2%). The objective response rate (ORR) was 79.2%, and the disease control rate (DCR) was 100%. At a median follow-up of 9.1 months, the estimated 1-year event-free survival (EFS) and overall survival (OS) rates were 80.8% and 88.9%, respectively. Treatment-related adverse events (TRAEs) were predominantly grade 1-2, with only 1 patient (4.2%) experiencing a grade 3 TRAE. No grade 4-5 TRAEs or treatment-related deaths occurred. There was 1 patient (5.0%) who experienced a grade 3 surgical complication. Conclusions: Neoadjuvant adebrelimab combined with triplet chemotherapy demonstrated acceptable perioperative feasibility, manageable toxicity, and preliminary pathological antitumor activity in patients with locally advanced AEG. Given the exploratory single-arm design and short follow-up, the findings should be considered hypothesis-generating and require validation in larger multicenter randomized trials.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
水煮电吹风的应助被suyi采纳,获得10
2秒前
Zuya完成签到 ,获得积分10
3秒前
机智铃铛给机智铃铛的求助进行了留言
3秒前
4秒前
8秒前
uppercrusteve完成签到,获得积分10
8秒前
李又又发布了新的文献求助10
9秒前
速写发布了新的文献求助10
9秒前
多喝烫水完成签到,获得积分10
10秒前
搜集达人的应助被4yjmngbfd采纳,获得10
11秒前
hhh发布了新的文献求助20
12秒前
Jasper的应助被李燕伟采纳,获得10
13秒前
月落流沙完成签到,获得积分10
13秒前
13秒前
77完成签到 ,获得积分10
14秒前
14秒前
15秒前
15秒前
uilyang完成签到,获得积分20
16秒前
17秒前
情怀的应助被千跃采纳,获得10
17秒前
17秒前
zijin完成签到,获得积分10
18秒前
粗心的若发布了新的文献求助10
18秒前
动听衬衫发布了新的文献求助10
19秒前
iuk完成签到,获得积分10
20秒前
相看两厌完成签到,获得积分10
21秒前
21秒前
李盈盈完成签到,获得积分20
22秒前
cindy完成签到,获得积分10
22秒前
As故完成签到,获得积分10
22秒前
22秒前
23秒前
笑点低愫完成签到,获得积分10
23秒前
iuk发布了新的文献求助10
24秒前
As故发布了新的文献求助10
24秒前
NEtizy完成签到 ,获得积分10
25秒前
NexusExplorer的应助被千跃采纳,获得10
25秒前
李燕伟发布了新的文献求助10
25秒前
laaaaaplace完成签到,获得积分10
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183621
求助须知:如何正确求助?哪些是违规求助? 9572918
关于积分的说明 21828010
捐赠科研通 7780809
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558243
邀请新用户注册赠送积分活动 2480496